文献速递肿瘤 PET/CT核素与放射性配体治疗

使用68Ga-Pentixafor PET对690例实体瘤或血液系统肿瘤患者进行C-X-C趋化因子受体4表达的显像

Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET.
PubMed 文献 · J Nucl Med · 2022-03-03

本研究对690例各类肿瘤患者共777次68Ga-Pentixafor PET/CT扫描进行半定量分析,评估CXCR4靶向显像的放射性药物摄取与图像对比度。535次扫描(68.9%)显示可辨认的病灶摄取,多发性骨髓瘤、肾上腺皮质癌、套细胞淋巴瘤、肾上腺皮质腺瘤和小细胞肺癌显示高摄取(SUVmax>12),多发性骨髓瘤、套细胞淋巴瘤和急性淋巴细胞白血病TBR>8。比活度与SUVmax或TBR无显著相关性(P≥0.612)。

要点

  • 68Ga-Pentixafor在多种肿瘤中显示高图像对比度,尤其血液系统恶性肿瘤、小细胞肺癌和肾上腺皮质肿瘤。
  • 多发性骨髓瘤(n=113)显示极高摄取(SUVmax>12),其次为肾上腺皮质癌(n=30)、套细胞淋巴瘤(n=20)、肾上腺皮质腺瘤(n=6)和小细胞肺癌(n=12)。
  • TBR>8见于多发性骨髓瘤、套细胞淋巴瘤和急性淋巴细胞白血病(n=6)。

核心结论

  • 在这个大型队列中,68Ga-Pentixafor在多种肿瘤中显示出高图像对比度,尤其是血液系统恶性肿瘤、小细胞肺癌和肾上腺皮质肿瘤。
  • 本分析可能为识别可能受益于CXCR4靶向治疗的患者提供路线图。

研究设计与样本

  • 共690例患有多种肿瘤的患者接受了总计777次68Ga-Pentixafor PET/CT扫描,68Ga-Pentixafor作为CXCR4特异性放射性配体。
  • 进行了半定量靶病灶分析,提供SUVmax和靶本比(TBR,定义为靶病灶的SUVmax除以血池的SUVmean)。
  • 将应用的比活度(MBq/μg)与半定量评估进行比较。

主要发现

  • 777次扫描中,242次未显示疾病部位可辨认的摄取,剩余535次PET扫描(68.9%)用于进一步分析。
  • 极高示踪剂摄取(SUVmax>12)见于多发性骨髓瘤(n=113),其次为肾上腺皮质癌(n=30)、套细胞淋巴瘤(n=20)、肾上腺皮质腺瘤(n=6)和小细胞肺癌(n=12)。
  • TBR>8见于多发性骨髓瘤、套细胞淋巴瘤和急性淋巴细胞白血病(n=6)。
  • 比活度与SUVmax或TBR比较,均无显著相关性(P≥0.612)。

关键数值与推荐

  • SUVmax>12:多发性骨髓瘤(n=113)、肾上腺皮质癌(n=30)、套细胞淋巴瘤(n=20)、肾上腺皮质腺瘤(n=6)、小细胞肺癌(n=12)。
  • TBR>8:多发性骨髓瘤、套细胞淋巴瘤和急性淋巴细胞白血病(n=6)。
  • 比活度与SUVmax或TBR无显著相关性(P≥0.612)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, molecular imaging addressing the C-X-C motif chemokine receptor 4 (CXCR4) has increasingly been used in various clinical settings. Here, we aimed to assess radiopharmaceutical uptake and image contrast to determine the most relevant clinical applications for CXCR4-directed imaging. We also investigated the impact of specific activity on scan contrast. Methods: Patients (n = 690) with a variety of neoplasms underwent a total of 777 PET/CT scans with 68Ga-Pentixafor, serving as the CXCR4-specific radioligand. A semiquantitative target lesion analysis was conducted (providing SUVmax and target-to-blood pool ratio [TBR], defined as SUVmax [from target lesion] divided by SUVmean [from blood pool]). The applied specific activity (in MBq/μg) was compared with semiquantitative assessments. Results: Of the 777 scans, 242 did not show discernible uptake in disease sites, leaving 535 PET scans (68.9%) for further analysis. Very high tracer uptake (SUVmax > 12) was found in multiple myeloma (n = 113), followed by adrenocortical carcinoma (n = 30), mantle cell lymphoma (n = 20), adrenocortical adenoma (n = 6), and small cell lung cancer (n = 12). Providing information on image contrast, comparable results for TBR were recorded, with TBR (>8) in multiple myeloma, mantle cell lymphoma, and acute lymphoblastoid leukemia (n = 6). When comparing specific activity with semiquantitative parameters, no significant correlation was found for SUVmax or TBR (P ≥ 0.612). Conclusion: In this large cohort, 68Ga-Pentixafor demonstrated high image contrast in a variety of neoplasms, particularly for hematologic malignancies, small cell lung cancer, and adrenocortical neoplasms. The present analysis may provide a roadmap for detecting patients who may benefit from CXCR4-targeted therapies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Buck AK, Haug A, Dreher N, et al. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET. J Nucl Med. 2022. PMID: 35241482. doi:10.2967/jnumed.121.263693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。